Changed Risks for GLYCOMIMETICS INC (GLYC)

Here are risks that changed year over year. risks from the recent filings of GLYCOMIMETICS INC. Our algorithms work hard to highlight risks unique to this company.

We incur increased costs and demands upon management as a result of being a public company

We expect to rely on third parties to conduct our future clinical trials for drug candidates other than rivipansel, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials

The FDA fast track designation for rivipansel and uproleselan and additional breakthrough therapy designation for uproleselan may not actually lead to a faster development or regulatory review or approval process